Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC

In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non –clear cell renal cell carcinoma (RCC).02/20/2019
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news